Posted by Michael Wonder on 10 Oct 2016
Elbit Imaging announces that Gamida Cell has received FDA breakthrough therapy designation for Nicord
10 October 2016 - Elbit Imaging announced today that it was informed by Gamida Cell, an indirect associate of the Company, that U.S. FDA has granted breakthrough therapy designation status to Gamida's NiCord, due to improvement in absorption of neutrophils blood cells in bone marrow transplant for patients with high risk hematological malignancies (blood cancers).
Gamida is engaged in developing cellular and immune therapies for the treatment of cancer and orphan genetic diseases. Gamida's products are examined via clinical trials for treatment of patients with hematological malignancies (blood cancers) such as leukemia and lymphoma and genetic hematological diseases such as sickle cell disease and thalassemia.
